Helicos BioSciences Corporation

Helicos BioSciences Announces Additions to Scientific Advisory Board

Helicos BioSciences Announces Additions to Scientific Advisory Board

December 12, 2006

Genomic Experts to Join Renowned Board of Thought Leaders

CAMBRIDGE, Mass.—(December 12, 2006)— Helicos BioSciences, pioneering new frontiers in genetic analysis, today announced the addition of John Quackenbush, Ph.D. of Dana-Farber Cancer Institute, and David Liu, Ph.D. of Harvard University, to its scientific advisory board.

Mascoma Corporation

Mascoma Awarded New York State Contract to Build and Operate $20 Million Cellulosic Ethanol Demonstration Facility

Mascoma Awarded New York State Contract to Build and Operate $20 Million Cellulosic Ethanol Demonstration Facility

December 20, 2006

Receives $14.8 million for project planned for Rochester, NY; Planning to partner with Genencor to supply advanced enzyme systems

Interactive Supercomputing Corporation

Interactive Supercomputing Reinforces Management Roster

Interactive Supercomputing Reinforces Management Roster

June 3, 2008

WALTHAM, MA--(Marketwire - June 3, 2008) - Interactive Supercomputing (ISC) strengthened its management team today, adding two new executives with extensive experience and talent in the technical computing industry. ISC board member, Bill Strecker, has formally joined the company as its chief technology officer (CTO), while former AMD HPC Marketing Director David Rich joins as vice president of marketing.

Affinity Express Management Team and LiveIt Acquire Outsourced Graphic and Design Services Leader

Affinity Express Management Team and LiveIt Acquire Outsourced Graphic and Design Services Leader

January 11, 2007

Chicago, January 11, 2007–James R. Daleen, president and chief executive officer of Affinity Express, Inc., announced that the company’s management team, in partnership with LiveIt Solutions, Inc., the holding company for Ayala Corporation’s investments in the Business Process Outsourcing (BPO) sector, has acquired 100% of the Delawareincorporated
company.

Affinity Express is the leading provider of outsourced graphic and design services for more than 3,000 clients worldwide in several industries, including:

IntelliVid

Retailers Invited to Participate in IntelliVid's Proof-of-Value Program to Test Its Video Analytics Solution

Retailers Invited to Participate in IntelliVid's Proof-of-Value Program to Test Its Video Analytics Solution

February 26, 2007

IntelliVid Proposes to Increase Retailers' Operating Incomes by Nine Percent by Decreasing Shrink 25 Percent
Cambridge, MA, February 26, 2007 -- IntelliVid Corporation today announced its Proof-of-Value Program, created to benchmark the effectiveness of video analytics systems in the retail industry.

Hypnion, Inc.

Hypnion Announces Positive and Robust Phase II Results for Novel Sleep Drug - HY10275

Hypnion Announces Positive and Robust Phase II Results for Novel Sleep Drug - HY10275

January 5, 2007

Primary and Secondary Efficacy Endpoints
Achieved Statistical Significance

Study Validated Drug's Unique H1 / 5HT2a
Mechanisms of Action

Drug Was Very Well Tolerated

Hypnion, Inc.

Lilly Announces Acquisition of Hypnion

Lilly Announces Acquisition of Hypnion

March 5, 2007

Deal Will Bolster Lilly's Sleep Disorder Research With Promising Insomnia Compound

Hypnion, Inc.

Lilly Announces Completion of Hypnion Acquisition

Lilly Announces Completion of Hypnion Acquisition

April 3, 2007

INDIANAPOLIS, April 3, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Eli Lilly and Company (NYSE: LLY) today announced that it has completed its acquisition of Hypnion, Inc., a privately held neuroscience drug discovery company focused on sleep disorder research.

AVEO Pharmaceuticals, Inc.

AVEO acquires Clinical Stage Anti-Cancer Compound from Kirin

AVEO acquires Clinical Stage Anti-Cancer Compound from Kirin

January 4, 2007

AVEO adds Phase II-ready VEGF receptor inhibitor to growing product portfolio

BG Medicine, Inc.

Flagship Portfolio Company BG Medicine Announces Major Collaborative Research Effort to Prevent Heart Attack & Stroke

Flagship Portfolio Company BG Medicine Announces Major Collaborative Research Effort to Prevent Heart Attack & Stroke

January 30, 2007

BG Medicine today announced the initiation of a multi-year research project, funded by Merck, AstraZeneca and Philips Medical, aimed at better understanding high risk plaque in heart attack and stroke.  The project will harness BGM’s systems biology measurement approaches along with state-of-the art medical imaging techniques to identify new approaches for the detection and treatment of vulnerable patients.